Science Corp. Secures $230M, Readies Vision-Restoring BCI for Market Launch
March 9, 2026, 4:11 am
Location: United States, Massachusetts, Lincoln
Employees: 201-500
Founded date: 1812
Location: United States, California, Mountain View
Employees: 51-200
Founded date: 2005
Science Corp. secured $230M in Series C funding. Total capital reached $490M. The neural engineering leader is poised to commercialize PRIMA, its vision-restoring BCI retinal implant for macular degeneration, across Europe. Clinical trials showed significant patient improvement. Regulatory approval is underway. Funds also fuel Biohybrid neural interfaces and Vessel organ perfusion systems. Science targets being the first BCI company with a market product, advancing deeptech beyond current boundaries.
Science Corporation recently announced a pivotal funding round. The Alameda, California company closed a $230 million Series C financing. This substantial investment pushes its total capital raised to approximately $490 million. The company, founded in 2021, operates in the cutting-edge field of neural engineering.
This capital infusion underscores strong investor confidence. Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital participated. This deeptech deal signals a significant shift. Investors now actively fund not only AI but also advanced neurotechnologies and biomedical platforms. Especially those nearing commercial viability. Science Corp. positions itself for a market breakthrough. It aims to be the first brain-computer interface (BCI) company to deliver a product to patients.
The immediate focus is PRIMA. PRIMA is a groundbreaking BCI retinal implant. It targets patients blinded by late-stage macular degeneration. This condition severely impairs vision. The implant is tiny. It is a microchip, smaller than a grain of rice. It measures just two millimeters. It works in conjunction with specialized glasses. These glasses house a camera. They project infrared light.
The retinal implant contains 378 pixels. Each pixel features a minute electrode. Infrared light strikes a pixel. This activates the attached electrode. The electrode then stimulates cells in the patient's retina. This process effectively substitutes retinal tissue lost to disease. It restores form vision.
Science acquired the PRIMA assets in 2024. The technology came from French company Pixium Vision. Science Corp. refined the technology. It then advanced its clinical program. Early trials have delivered impressive results. Studies included 47 patients across Europe and the U.S. Eighty percent demonstrated substantial improvement in visual acuity. Many could read letters, numbers, and words. These outcomes were published in The New England Journal of Medicine. They also featured on the cover of Time magazine. These compelling results were crucial for securing the new funding. They strengthen the investment case for rapid commercialization.
The regulatory path for PRIMA is now clear. Science Corp. submitted a CE mark application in the European Union. A decision is anticipated in mid-2026. European commercial launch is slated for later this year. Germany is a likely initial market. It offers mechanisms for early access to new medical technologies. Parallel discussions continue with the U.S. Food and Drug Administration (FDA) for regulatory approval. Successful clearance in Europe would mark Science as the first BCI company with a commercial product. This achievement would be a major milestone in medical technology.
Science is also broadening PRIMA's clinical reach. The program now includes Stargardt disease and retinitis pigmentosa. These inherited retinal conditions cause progressive vision loss. They often affect younger adults. Expanding indications significantly increases the addressable market. This also enhances the technology's future monetization potential. New trials will commence in Australia. Dr. Matthew Simunovic, a leader in prosthetic vision research, will lead the study. It will take place at Sydney Eye Hospital.
Science Corp.'s ambitions extend beyond PRIMA. The new capital will also fuel a wider R&D portfolio. One key area is the Biohybrid neural interface. This advanced BCI promises significantly more bandwidth than existing implants. More bandwidth means broader functionality. Biohybrid involves growing engineered neurons from stem cells. These neurons are placed on a device on the brain's surface. They form biological connections with existing neural networks. The system transmits data using electrodes and microLEDs.
Another critical development is the Vessel perfusion platform. This new business focuses on organ preservation technologies. Its goal is revolutionary. It aims to create miniaturized perfusion systems. These systems would enable organ transport on commercial flights. They could also sustain organs outside intensive care units. Vessel systems promise less manual operation than current equipment. They feature swappable components for patient customization. This technology could transform organ transplantation and life support.
Science Corp. also develops crucial supporting technologies. Axon Probes are sensors for neuroscientists. They facilitate data collection in laboratory experiments. These probes integrate with SciFi. SciFi is a miniature computer. It features a battery, 128 gigabytes of storage, and a Wi-Fi 6 modem. SciFi transmits scientific measurements efficiently. Scientists can program SciFi using Synapse. Synapse is an application programming interface. It allows deployment of custom data analytics programs. These programs automate complex data analysis. They are written in C++ and packaged into Docker containers.
The company maintains a vertically integrated approach. It manufactures custom chips at its North Carolina facility. Science acquired this fab in 2022. The new funding will expand its manufacturing capacity. It will also finance ongoing research initiatives. This integration ensures quality control and accelerates development.
Science Corp. is building a comprehensive neural engineering platform. Its mission is clear. It aims to address critical unmet medical needs. It also seeks to transform the human condition. This involves developing BCI technologies to treat severe conditions. It ultimately strives to expand the capabilities of human biology. The company's strategy is not to be "another BCI startup." It aims to be the first to commercialize a neurointerface. It tackles a profound medical problem: restoring sight. This approach resonates with investors. Its robust clinical data and clear regulatory path attract strong financial backing. Science combines scientific complexity with market proximity. This makes it a formidable player in the deeptech landscape. The $230 million investment is a testament to its potential. It signifies a future where neural engineering profoundly impacts human health.
Science Corporation recently announced a pivotal funding round. The Alameda, California company closed a $230 million Series C financing. This substantial investment pushes its total capital raised to approximately $490 million. The company, founded in 2021, operates in the cutting-edge field of neural engineering.
This capital infusion underscores strong investor confidence. Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital participated. This deeptech deal signals a significant shift. Investors now actively fund not only AI but also advanced neurotechnologies and biomedical platforms. Especially those nearing commercial viability. Science Corp. positions itself for a market breakthrough. It aims to be the first brain-computer interface (BCI) company to deliver a product to patients.
The immediate focus is PRIMA. PRIMA is a groundbreaking BCI retinal implant. It targets patients blinded by late-stage macular degeneration. This condition severely impairs vision. The implant is tiny. It is a microchip, smaller than a grain of rice. It measures just two millimeters. It works in conjunction with specialized glasses. These glasses house a camera. They project infrared light.
The retinal implant contains 378 pixels. Each pixel features a minute electrode. Infrared light strikes a pixel. This activates the attached electrode. The electrode then stimulates cells in the patient's retina. This process effectively substitutes retinal tissue lost to disease. It restores form vision.
Science acquired the PRIMA assets in 2024. The technology came from French company Pixium Vision. Science Corp. refined the technology. It then advanced its clinical program. Early trials have delivered impressive results. Studies included 47 patients across Europe and the U.S. Eighty percent demonstrated substantial improvement in visual acuity. Many could read letters, numbers, and words. These outcomes were published in The New England Journal of Medicine. They also featured on the cover of Time magazine. These compelling results were crucial for securing the new funding. They strengthen the investment case for rapid commercialization.
The regulatory path for PRIMA is now clear. Science Corp. submitted a CE mark application in the European Union. A decision is anticipated in mid-2026. European commercial launch is slated for later this year. Germany is a likely initial market. It offers mechanisms for early access to new medical technologies. Parallel discussions continue with the U.S. Food and Drug Administration (FDA) for regulatory approval. Successful clearance in Europe would mark Science as the first BCI company with a commercial product. This achievement would be a major milestone in medical technology.
Science is also broadening PRIMA's clinical reach. The program now includes Stargardt disease and retinitis pigmentosa. These inherited retinal conditions cause progressive vision loss. They often affect younger adults. Expanding indications significantly increases the addressable market. This also enhances the technology's future monetization potential. New trials will commence in Australia. Dr. Matthew Simunovic, a leader in prosthetic vision research, will lead the study. It will take place at Sydney Eye Hospital.
Science Corp.'s ambitions extend beyond PRIMA. The new capital will also fuel a wider R&D portfolio. One key area is the Biohybrid neural interface. This advanced BCI promises significantly more bandwidth than existing implants. More bandwidth means broader functionality. Biohybrid involves growing engineered neurons from stem cells. These neurons are placed on a device on the brain's surface. They form biological connections with existing neural networks. The system transmits data using electrodes and microLEDs.
Another critical development is the Vessel perfusion platform. This new business focuses on organ preservation technologies. Its goal is revolutionary. It aims to create miniaturized perfusion systems. These systems would enable organ transport on commercial flights. They could also sustain organs outside intensive care units. Vessel systems promise less manual operation than current equipment. They feature swappable components for patient customization. This technology could transform organ transplantation and life support.
Science Corp. also develops crucial supporting technologies. Axon Probes are sensors for neuroscientists. They facilitate data collection in laboratory experiments. These probes integrate with SciFi. SciFi is a miniature computer. It features a battery, 128 gigabytes of storage, and a Wi-Fi 6 modem. SciFi transmits scientific measurements efficiently. Scientists can program SciFi using Synapse. Synapse is an application programming interface. It allows deployment of custom data analytics programs. These programs automate complex data analysis. They are written in C++ and packaged into Docker containers.
The company maintains a vertically integrated approach. It manufactures custom chips at its North Carolina facility. Science acquired this fab in 2022. The new funding will expand its manufacturing capacity. It will also finance ongoing research initiatives. This integration ensures quality control and accelerates development.
Science Corp. is building a comprehensive neural engineering platform. Its mission is clear. It aims to address critical unmet medical needs. It also seeks to transform the human condition. This involves developing BCI technologies to treat severe conditions. It ultimately strives to expand the capabilities of human biology. The company's strategy is not to be "another BCI startup." It aims to be the first to commercialize a neurointerface. It tackles a profound medical problem: restoring sight. This approach resonates with investors. Its robust clinical data and clear regulatory path attract strong financial backing. Science combines scientific complexity with market proximity. This makes it a formidable player in the deeptech landscape. The $230 million investment is a testament to its potential. It signifies a future where neural engineering profoundly impacts human health.